Last updated: October 5, 2026
Novartis licensed Abogen’s mRNA encoded T cell engager for $575 million upfront and up to $7.8 billion total, CSL paid Alentis $355 million upfront for lixudebart, and Genmab’s Rina-S posted a 45.9% confirmed response rate in platinum resistant ovarian cancer.
This briefing covers the weekend of October 2 through October 4, 2026: two major licensing deals, new ovarian cancer data at IGCS 2026, an FDA review extension for Novo Nordisk, Friday’s approvals, and the catalysts arriving this week.
What did Novartis agree to pay Abogen?
Novartis will pay Suzhou based Abogen Biosciences $575 million upfront, with up to roughly $7.2 billion in development, regulatory, and commercial milestones plus royalties, for rights to ABO2203 and an option on additional programs from Abogen’s RNA platform. The total potential value is up to $7.8 billion. The companies announced the agreement on Friday, October 2.
ABO2203 is an mRNA encoded T cell engager directed at CD3 and CD19. Abogen has generated first in human data in relapsed or refractory B cell non-Hodgkin lymphoma, and the companies intend to develop the asset in autoimmune diseases, where CD19 directed cell and engager therapies have become one of the industry’s most crowded research fronts. Per the release as carried by BioSpace and BioPharma Dive, Abogen reported no cytokine release syndrome, no dose limiting toxicities, and no neurological complications among the first nine patients treated. Nine patients is a safety signal, not a profile; the figure is the company’s own characterization of an early dataset.
| Term | Detail |
|---|---|
| Upfront | $575 million |
| Milestones | Up to ~$7.2 billion (development, regulatory, commercial) |
| Total potential | Up to $7.8 billion plus royalties |
| Lead asset | ABO2203, mRNA encoded CD3xCD19 T cell engager, Phase 1 |
| Option | License rights to additional programs from Abogen’s RNA platform |
| Focus | Autoimmune disease, with B cell non-Hodgkin lymphoma data in hand |
Fiona Marshall, Novartis’ head of biomedical research, said the approach could complement existing modalities by “enabling in vivo production,” per BioPharma Dive. Novartis shares closed Friday at $141.00.
What is an mRNA encoded T cell engager?
A conventional T cell engager is a bispecific antibody manufactured in a bioreactor, purified, and infused on a schedule. An mRNA encoded engager ships the instructions instead of the protein: lipid nanoparticle delivered mRNA directs the patient’s own cells to produce the engager internally, for a limited time. The hoped for advantages are a gentler onset that could reduce cytokine release risk, redosing flexibility, and a manufacturing footprint closer to a vaccine plant than an antibody facility. The open questions are durability of expression, immunogenicity over repeated cycles, and whether in vivo production can be controlled tightly enough for chronic autoimmune use. No mRNA encoded engager has reached a pivotal trial.
What did CSL buy from Alentis?
CSL will pay Swiss biotech Alentis Therapeutics $355 million upfront, with up to $1.2 billion in commercial milestones, for a global partnership on lixudebart, an antibody against claudin-1. After commercialization the companies would split profits 55% to CSL and 45% to Alentis. The release crossed Sunday evening, October 4, at 5:42 pm ET.
Lixudebart targets exposed claudin-1, which Alentis describes as a driver of inflammatory and fibrotic signaling. The lead program is ANCA associated vasculitis with rapidly progressive glomerulonephritis, where the Phase 2 RENAL trial is ongoing and a Phase 3 is planned. Phase 2 studies are planned in focal segmental glomerulosclerosis and primary sclerosing cholangitis. CSL takes on full funding of the specified trials; the companies jointly develop and co promote. For CSL, which has spent two years under pressure to show where growth beyond plasma comes from, this is a clinical stage rare disease bet squarely inside its renal and hepatic franchises. Some outlets rounded the deal to $1.6 billion; the release components are $355 million upfront and up to $1.2 billion in milestones.
How effective was Genmab’s Rina-S in platinum resistant ovarian cancer?
In Part C of the Phase 2 RAINFOL-01 trial, rinatabart sesutecan (Rina-S) at 120 mg/m2 every three weeks produced a 45.9% confirmed objective response rate among 109 treated patients with platinum resistant ovarian cancer, including five complete responses. Genmab released the data Saturday, October 3, alongside a presentation at the International Gynecologic Cancer Society annual meeting.
| RAINFOL-01 Part C (release figures) | Result |
|---|---|
| Patients treated | 109 |
| Confirmed objective response rate | 45.9% (5 complete responses) |
| Median duration of response | 12.1 months |
| Responders still in response at one year | 51% |
| Median progression free survival | 9.5 months |
| Discontinuations for adverse events | 5.5% |
Two claims in the release matter beyond the headline rate. First, Genmab reported antitumor activity across all levels of folate receptor alpha expression, including patients with no detectable FRα. Second, the company reported no safety signals for ocular toxicity, peripheral neuropathy, interstitial lung disease, or stomatitis, the four liabilities that define the folate receptor ADC class. Serious adverse events occurred in roughly a third of patients. The Phase 3 confirmatory trial, RAINFOL-02, is enrolling at the same dose. Genmab closed Friday at $34.75 before the release; Monday is the first reaction session.
Why did the FDA extend its review of Novo Nordisk’s denecimig?
The FDA extended its review of the denecimig biologics license application, citing ongoing facility remediation activities, and communicated no new action date. Novo Nordisk said the agency identified no deficiencies in the clinical efficacy or safety data. The company now aims to launch the hemophilia A therapy in the US in the first half of 2027.
Denecimig is under review for hemophilia A with or without inhibitors in adults and children. The release crossed Friday at 4:53 pm ET, after the close, so Monday is the first reaction session for Novo’s ADRs, which ended Friday at $37.32 before the news. The notable feature is the failure mode: a BLA with clean clinical data held up by a plant. Novo said the extension does not affect its 2026 outlook.
What else did the FDA approve on Friday?
The FDA approved Eli Lilly’s Jaypirca (pirtobrutinib) for adults with previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma with no known 17p deletion, moving the non covalent BTK inhibitor into first line use. In BRUIN CLL-313, pirtobrutinib cut the risk of progression or death by 80% versus bendamustine plus rituximab.
| BRUIN CLL-313 (FDA approval notice) | Pirtobrutinib (n=141) | Bendamustine + rituximab (n=141) |
|---|---|---|
| Median progression free survival | Not estimable | 33.5 months |
| Hazard ratio | 0.20 (95% CI 0.11 to 0.37; p<0.0001) | |
| Deaths at 28 month median follow up | 3 (2.1%) | 10 (7.1%) |
Overall survival data remain immature, and serious adverse reactions occurred in 28% of pirtobrutinib patients. The commercial question is sequencing: Jaypirca built its franchise as the drug that works after covalent BTK inhibitors fail, and a Lilly executive told Fierce Pharma the drug’s “primary use remains in second line” even with the new label. Playing the salvage card first is now an option the field will have to price.
On the device side, the FDA granted premarket approval to Edwards Lifesciences’ Autus valve, the first size adjustable pediatric pulmonary valve, per MedTech Dive. The valve uses synthetic polymer leaflets rather than animal tissue, is implanted at roughly 13 mm, and can be expanded by balloon catheter to 22 mm as a child grows, replacing repeat open heart surgeries with a catheter procedure. Edwards said the pivotal study of 62 children met its primary safety and effectiveness endpoints; three patients had valve frame fractures and two had reduced leaflet motion without symptoms.
What is Bayer building in Ohio?
Bayer will invest $2.2 billion in a new pharmaceutical manufacturing campus in New Albany, Ohio, combining drug substance and drug product production in a flexible modular design supporting its oncology, cardiovascular, and renal portfolio. The company expects about 600 permanent jobs and roughly 1,500 construction jobs, with the first module operational in 2031 and a second in 2034.
The timeline is the message. A first module five years out means the investment answers structural pressure, not a quarter’s tariff headline: US onshoring commitments have now become table stakes for European pharma operating under the tariff framework and the administration’s pricing lattice. Announced Thursday by a different route, the FDA’s extension of denecimig over facility remediation shows the same lever from the other side. Capacity, compliance, and geography are becoming binding constraints on when medicines reach the market.
What does Vaxcyte report on Monday?
Vaxcyte presents topline results from OPUS-1, the pivotal adult Phase 3 trial of VAX-31, its 31 valent pneumococcal conjugate vaccine candidate, on a webcast Monday, October 5 at 8:00 am ET. The readout covers safety, tolerability, and immunogenicity. The data had not been released as of Sunday night; nothing about the outcome is known yet.
VAX-31 is the vaccine sector’s most consequential near term readout. A clean immunogenicity result against the licensed comparator would position the broadest conjugate vaccine yet constructed for a pivotal filing path in adults, in a market Pfizer and Merck currently split. Vaxcyte closed Friday at $56.48 ahead of the data.
Which stocks moved on Friday, and what do the moves say?
Five Friday closes carry a story. All moves are computed from exchange settled closes; percentage changes are our arithmetic.
| Company | Friday close | Move | Why it matters |
|---|---|---|---|
| Foghorn (FHTX) | $2.02 | −30.8% (second session) | The post Lilly exit slide extended; the two session loss from $3.57 is 43.4%. Preclinical validation is repricing to clinical proof. |
| Cullinan (CGEM) | $15.51 | +6.7% (first reaction) | First session after the first line zipalertinib rolling NDA under RTOR; the market paid for the earlier line. |
| Axogen (AXGN) | $37.39 | −6.3% (first reaction) | First session after the BioCircuit close; the market asked what NerveTape integration costs before it pays for the franchise. |
| Kodiak (KOD) | $94.45 | −4.1% | The four session Zenkuda repricing run paused ahead of the Q4 BLA submission window. |
| Vaxcyte (PCVX) | $56.48 | Pre data close | The last print before Monday’s OPUS-1 topline; the reference point for the readout. |
Frequently asked questions
How much did Novartis pay Abogen upfront?
$575 million upfront, with up to roughly $7.2 billion in milestones and royalties on sales, for a total potential value of up to $7.8 billion, per the companies’ October 2 announcement.
What is ABO2203?
ABO2203 is Abogen’s mRNA encoded T cell engager targeting CD3 and CD19. Lipid nanoparticle delivered mRNA directs the patient’s cells to produce the engager in vivo. It has first in human data in B cell non-Hodgkin lymphoma and is being pointed at autoimmune disease.
Why would Novartis want an mRNA encoded engager for autoimmune disease?
CD19 directed therapies have shown deep B cell resets in autoimmune conditions, but cell therapy logistics limit scale. An mRNA delivered engager, if it works, would be an off the shelf, redosable route to the same biology with vaccine like manufacturing.
What are the terms of the CSL and Alentis partnership?
CSL pays $355 million upfront plus up to $1.2 billion in commercial milestones for a global partnership on lixudebart; after commercialization, profits split 55% CSL and 45% Alentis, with CSL funding the specified trials.
What is lixudebart?
Lixudebart is an antibody against exposed claudin-1, a target in inflammatory and fibrotic disease. It is in the Phase 2 RENAL trial in ANCA associated vasculitis with rapidly progressive glomerulonephritis, with planned studies in focal segmental glomerulosclerosis and primary sclerosing cholangitis.
What response rate did Rina-S show in ovarian cancer?
A 45.9% confirmed objective response rate in 109 treated patients with platinum resistant ovarian cancer, including five complete responses, with a 12.1 month median duration of response and 9.5 month median progression free survival, per Genmab’s October 3 release.
Why does the FRα finding matter for Rina-S?
Genmab reported activity across all folate receptor alpha expression levels, including undetectable FRα. The approved competitor in this setting is labeled for FRα high tumors, so an expression agnostic profile, if confirmed in Phase 3, would widen the addressable population.
Is Rina-S approved?
No. Rina-S is investigational. The Phase 3 RAINFOL-02 trial at the same 120 mg/m2 dose is the confirmatory study behind any filing.
Why was the denecimig BLA review extended?
The FDA cited ongoing facility remediation activities. Novo Nordisk said the agency found no deficiencies in clinical efficacy or safety data, communicated no new action date, and that the company now aims for a US launch in the first half of 2027.
What did the FDA approve Jaypirca for on October 2?
Previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma with no known 17p deletion, based on BRUIN CLL-313, where pirtobrutinib showed a 0.20 hazard ratio for progression or death versus bendamustine plus rituximab.
What is the Autus valve?
Edwards Lifesciences’ pediatric pulmonary valve with synthetic polymer leaflets, approved by the FDA as the first size adjustable option: implanted at about 13 mm and balloon expandable to 22 mm as the child grows, reducing repeat open heart surgeries.
What will Bayer’s Ohio site manufacture?
Drug substance and drug product for Bayer’s oncology, cardiovascular, and renal medicines, in a modular campus in New Albany, Ohio; the first module is expected to be operational in 2031.
When does Vaxcyte report OPUS-1 data?
Monday, October 5, 2026, on a webcast at 8:00 am ET, covering topline safety, tolerability, and immunogenicity for VAX-31 in adults. The outcome was not public as of Sunday night.
What happened with the ADARx greenshoe?
The underwriters exercised their option in full: 3,937,500 additional shares at $17.00, closing announced October 1, bringing IPO gross proceeds to about $513.2 million and roughly $602.5 million including AbbVie’s concurrent private placement.
Sources
Primary sources (October 2 to 4, 2026): Abogen Biosciences press release (October 2, via BioSpace and BioPharma Dive carries); CSL and Alentis press release (October 4); Genmab press release on RAINFOL-01 Part C (October 3, via RTTNews carry); Novo Nordisk press release on the denecimig BLA (October 2); FDA approval notice for pirtobrutinib (October 2); Bayer press release on the New Albany site (October 2); Summit Therapeutics press release on the Datroway collaboration (October 2); Vaxcyte press release on the OPUS-1 webcast (October 4); ADARx Pharmaceuticals press release (October 1); Edwards Lifesciences statement per MedTech Dive (October 2).
Trade coverage: BioSpace, BioPharma Dive, Fierce Biotech, Fierce Pharma, MedTech Dive, Endpoints News headlines, RTTNews. Market closes are exchange settled closing prices for Friday, October 2, 2026; percentage moves are our arithmetic from verified closes.
Related coverage
Friday’s edition: Regeneron’s trevogrumab preserved muscle lost on semaglutide at 52 weeks as Sanofi paid $1 billion for four Dupixent successors
Thursday’s edition: Lilly’s eloraTZP cut weight 23.3% in Phase 2 as Foundayo passed its cardiovascular safety test and CMS finalized the GLOBE rule
Last Tuesday’s edition: Lilly’s retatrutide cut weight 20.8% in Phase 3 as uniQure’s Huntington’s benefit weakened at 48 months
